Physician profile
William Mirabal
NPI 1891237962
$4,744.84
in general payments reported to CMS, 2019-2025
23 companies · $638 in 2025
The $638 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,031 · 2022: $440 · 2023: $1,894 · 2024: $742 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,522 · Travel and Lodging: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,522.10 |
| Travel and Lodging | $752.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,336.82 | 2023 | Indigo System |
| Boston Scientific Corporation | $745.36 | 2021-2025 | Watchman Flx, Farapulse, Lux-Dx Insertable Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $464.00 | 2021-2025 | Lifevest |
| Abiomed | $389.71 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $378.78 | 2021-2025 | |
| Abbott Laboratories | $306.44 | 2022-2025 | Amplatzer Amulet, Cardiomems, Aveir |
| Medtronic, INC. | $269.80 | 2021-2025 | Corevalve Evolut R |
| Edwards Lifesciences Corporation | $204.11 | 2021-2024 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals Lp | $191.86 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $130.07 | 2023 | Gore Cardioform Septal Occluder |
| Impulse Dynamics (USA) INC. | $60.94 | 2021 | |
| Amgen INC. | $33.91 | 2021 | |
| Janssen Pharmaceuticals, INC | $32.47 | 2021 | |
| Atricure, INC. | $30.62 | 2024 | |
| Philips North America LLC | $27.57 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $27.02 | 2024 | True Dilatation |
| Cardiva Medical, INC. | $22.67 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Merck Sharp & Dohme LLC | $22.41 | 2021 | |
| Acist Medical Systems, INC. | $16.62 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.40 | 2021 | |
| Davol INC. | $13.59 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.98 | 2021 | |
| Lundbeck LLC | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mirabal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.